NHS Forth Valley played a key role in the OPTIMA international study, which could transform breast cancer treatment by reducing chemotherapy use. The study, funded by the National Institute for Health Research (NIHR) and led by University College London (UCL), aimed to improve decision-making for patients with hormone-sensitive early breast cancer.
Study Details and Local Recruitment
Forth Valley Royal Hospital opened the study locally in 2013 with an initial target of 15 patients. Thanks to strong engagement, 62 patients were recruited—over four times the original target. Across the UK, 4,821 patients participated at more than 100 hospitals, making OPTIMA one of the largest trials of its kind.
Key Findings and Impact
Recent findings suggest that many patients could safely avoid chemotherapy. The study used the Prosigna DNA-based test to identify which patients benefit from chemotherapy and which can be treated with hormone therapy alone. Results indicate that around two-thirds of patients did not require chemotherapy, potentially shifting clinical practice and reducing side effects and NHS resource demands.
Local Team Contributions
NHS Forth Valley's Research & Development team, led by Principal Investigator Dr Judy Fraser, included Research Nurses Karen Petrie, Anna Hamilton, and Laura McGenily, along with Breast Cancer Nursing Teams. They ensured patients were fully informed and supported throughout the study and follow-up, which continues for up to 10 years after surgery.
Patient Testimonial
One local participant shared: “Following my breast cancer diagnosis, initial treatment discussed included surgery, chemotherapy and radiotherapy. Having witnessed a close relative being very unwell following chemotherapy, I was very apprehensive. The OPTIMA trial was discussed and I agreed to participate. I was subsequently informed that chemotherapy was not required. I felt very relieved. I was delighted to see the recent results and feel very grateful to have taken part in research that could improve treatment for future patients.”
Broader Implications
The OPTIMA study represents a significant step in personalised cancer care. Wider adoption of genomic testing like Prosigna could ensure patients receive the most appropriate treatment. For NHS Forth Valley, contributing to this scale of research highlights the vital role of local teams in advancing patient care and supporting NHS innovation.
